In the future, it may be worth to assess the tumor microenvironment, explore practical immune-related predictive biomarkers of efficacy, and apply ICIs combined with anti-HER2 therapy in early-stage or first-line setting of HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.